CTS5 Risk Model vs 21-Gene Recurrence Score Assay and the Development of a Novel Nomogram for Predicting Survival in HR+ Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Breast
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Comparison of CTS5 risk model and 21-gene recurrence score assay in large-scale breast cancer population and combination of CTS5 and recurrence score to develop a novel nomogram for prognosis prediction
Breast 2022 Jun 01;63(xx)61-70, C Wang, Y Xu, Y Lin, Y Zhou, F Mao, X Zhang, S Shen, Y Zhang, Q SunFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.